DAFNA Capital Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

DAFNA Capital Management’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,999	Closed	-$166K	–	87
2018 Q1	$166K	Buy	+1,999	New	+$227K	0.08%	69
2017 Q4	–	Sell	-1,100	Closed	-$68K	–	80
2017 Q3	$68K	Sell	1,100 -5,525	-83%	-$324K	0.04%	72
2017 Q2	$310K	Hold	6,625	–	–	0.22%	59
2017 Q1	$405K	Buy	+6,625	New	+$385K	0.34%	57
2016 Q2	–	Sell	-250	Closed	-$67K	–	106
2016 Q1	$67K	Hold	250	–	–	0.06%	86
2015 Q4	$150K	Buy	250 +37	+17%	+$25K	0.13%	70
2015 Q3	$174K	Buy	+213	New	+$240K	0.17%	74

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DAFNA Capital Management's SRRA Position: Q2 2018 in Review

DAFNA Capital Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2018, closing a stake of 1,999 shares — an estimated $166K sold.

DAFNA Capital Management first reported a position in SRRA in Q3 2015 and held it in 7 quarters. The position peaked at $405K in Q1 2017. 70 funds tracked by Wall St. Rank hold SRRA as of Q2 2018.

DAFNA Capital Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
DAFNA Capital Management sold 1,999 Sierra Oncology, Inc. Common Stock shares in Q2 2018, an estimated $166K.
DAFNA Capital Management first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 7 quarters.
DAFNA Capital Management's Sierra Oncology, Inc. Common Stock position peaked at $405K in Q1 2017.
70 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2018.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.